Platform provides real-time visibility on process development and GMP manufacturing. Read More >>
InduPro to license Lonza’s linker payload technologies and bioconjugation platforms to help advance its ADC therapeutics.
Our enhanced offering enables mAb programs to achieve IND readiness in as little as 6 months, with tox‑grade DS available in ~2 months.
Companies aim to de-risk and accelerate development for clients by combining capabilities.
Successfully tech-transferred and manufactured first commercial-scale GMP batches of Renaissance Pharma’s lead candidate, Daretabart.
How to compare CMO proposals and know what your true costs will be.
Will provide microbial contract development and manufacturing services for the recombinant human matrix metalloproteinase-7.
With expertise in traditional and advanced therapies, Cardinal Health Regulatory Sciences will collaborate throughout the product lifecycle to help achieve your regulatory goals. Learn more.
